October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ...
Cardiovascular diseases remain the leading cause of mortality globally, encompassing a range of disorders that affect the heart and blood vessels, including but not limited to ischemic heart disease, ...
Pluripotent stem cells are cells that have the capacity ... maturation and assessment techniques for in vitro hiPSC-derived cardiomyocyte models and makes recommendations for standardizations ...
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy ...